Skip to main content
COCH
NASDAQ Industrial Applications And Services

Envoy Medical Reports Q2 2026 Results, Submits First PMA Module to FDA, and Posts Positive 12-Month Trial Data

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$0.705
Mkt Cap
$54.201M
52W Low
$0.363
52W High
$1.89
52W Position info
94% above low
Off High info
63% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

COCH sits 94% above its 52-week low of $0.363.

Summary

Envoy Medical reported Q2 2026 results with a $7.3M net loss and $19.7M in cash, submitted the first module of its PMA application to the FDA, and announced positive 12-month data from its pivotal cochlear implant trial.


Key Events · Earnings and Guidance · COCH

  • Q2 2026 Financial Results

    Net loss of $7.3 million ($0.07 per share) on minimal revenue of $51,000. R&D expenses rose to $3.1 million, reflecting clinical trial and PMA submission costs. Cash stood at $19.7 million as of June 30, 2026.

  • First PMA Module Submitted to FDA

    The company submitted the first of four modules of its modular PMA application for the Acclaim cochlear implant, with the final module targeted for Q2 2027. This initiates FDA review and provides a defined regulatory cadence.

  • Positive 12-Month Trial Data

    The first 10 patients in the pivotal trial achieved a mean CNC word recognition score of 53.2% at 12 months, a 38.0 percentage point improvement from baseline, demonstrating continued speech perception gains.

  • Full Trial Cohort Passes Three-Month Follow-Up

    All 56 patients in the pivotal trial have surpassed the three-month follow-up window, marking a key clinical milestone as the study advances toward the primary efficacy endpoint at 12 months.


Analysis · COCH · Industrial Applications And Services

Envoy Medical's Q2 2026 results show a net loss of $7.3 million and cash of $19.7 million, providing runway only through Q1 2027 per the recent 10-Q. The company submitted the first module of its modular PMA application to the FDA and reported positive 12-month data from its pivotal Acclaim cochlear implant trial, with a mean CNC word recognition score of 53.2% versus a 15.2% baseline. These milestones advance the regulatory timeline, but the persistent going concern risk and near-term cash needs remain critical. The termination of the ATM facility removes a potential overhang but also eliminates a source of capital.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COCH was trading at $0.71 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $54.2M. The 52-week trading range was $0.36 to $1.89. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COCH - Latest Insights

COCH
Nov 05, 2026, 1:56 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.05
Real-time Price: $7.11 info
Change: +$0.065 (+0.92%) info
Market Cap: $54.95M info
COCH
Nov 05, 2026, 7:10 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.12
Real-time Price: $7.11 info
Change: -$0.0100 (-0.14%) info
Market Cap: $54.95M info
COCH
Aug 31, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.720
Real-time Price: $7.11 info
Change: Reverse Stock Split info
Market Cap: $54.95M info
COCH
Aug 19, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.740
Real-time Price: $7.11 info
Change: Reverse Stock Split info
Market Cap: $54.95M info
COCH
Aug 10, 2026, 8:31 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.6932
Real-time Price: $7.11 info
Change: Reverse Stock Split info
Market Cap: $54.95M info